Research Article

Upregulation of CD146 in Pediatric B-Cell Acute Lymphocytic Leukemia and Its Implications on Treatment Outcomes

Asmaa M. Zahran,1 Omnia El-Badawy,2 Khalid I. Elsayh,3 Wael M. Y. Mohamed,4 Khalid F. Riad,5 Mona H. Abdel-Rahim,2 and Amal Rayan6

1Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
2Medical Microbiology & Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
3Pediatric Department, Faculty of Medicine, Assiut University, Assiut, Egypt
4Oncology Department, Faculty of Medicine, Port Said University, Port Said, Egypt
5Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
6Clinical Oncology Department, Assiut University Hospital, Assiut University, Assiut, Egypt

Correspondence should be addressed to Amal Rayan; amal3774rayan@gmail.com

Received 25 September 2019; Accepted 30 December 2019; Published 8 February 2020

Academic Editor: Baohui Xu

Copyright © 2020 Asmaa M. Zahran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aim. We studied through flow cytometry the expression of CD146 on different T cells, and B-cell ALL blasts trying to correlate its expression with different prognostic factors of B-cell ALL and treatment outcomes. Patients and Methods. All pediatric patients with B-cell ALL were subjected to bone marrow examination and cytochemistry, flow cytometric immunophenotyping using monoclonal antibodies utilized for diagnosis of B-ALL including CD34, CD19, CD10, CD22, and intracellular IgM. The diagnosis was based on standard morphologic, cytochemical, and immunophenotypic followed by flow cytometric detection of CD146 expression on blast cells, CD4+, and CD8+ T cells. Results. Significant accumulations of CD146+CD4+ cells, CD146+CD8+ cells, CD4+, CD8+, and lymphocytes in patients were compared to controls, the mean percentages of CD146+CD4+ cells, CD146+CD8+ cells, and CD146+ blasts were significantly higher in patients than controls, and in addition, these cells were associated with poor overall survival and disease-free survival. The median OS for patients with complete response was 22 ± 1.633 (95%CI = 18.799-25.201), while for those without complete response, it was 13 ± 3.928 (95%CI = 5.301-25.699), with log-rank = 5.71, P = 0.017. Conclusion. CD146 was expressed significantly in children’s B-ALL and associated with poor prognostic features including poor response and treatment outcomes and could be a possible poor prognostic factor in pediatric B-cell ALL.

1. Introduction

Acute lymphoblastic leukemia (ALL) is by far the most common pediatric malignancy, representing one quarter of all children cancers. Annually, there are 3.7-4.9 cases of ALL per 100,000 children aged 0-14 years in USA [1]. The exact risk factors for developing ALL have yet defined; most studies revealed mixed results with both maternal and infant causes which have been accused including maternal age, birth weight and order, smoking, and pesticide exposure.

With improvements in diagnostic and treatment modalities, overall cure rates for pediatric ALL have reached 90% [2]; the use of risk-adapted treatment protocols has improved cure rates while minimizing the toxicity of therapy. CD146, also known as Mel-CAM, MUC18, MCAM, S-Endo-1, and P1H12 antigen [3], is a transmembrane glycoprotein belonging to the immunoglobulin family and functions as a Ca2+-independent adhesion molecule [4]. It is expressed in normal tissues including smooth muscles, vascular endothelium, and others to exert cation-independent adhesion through interactions with an unidentified ligand.
on the surface of various cells [5]; further studies revealed that CD146 has multifunctional activities both in physiological and pathological conditions including immunity, angiogenesis, and development.

A growing number of studies suggested that CD146 overexpression was significantly correlated with progression, angiogenesis, and metastasis of different malignant tumors like esophageal cancer, melanoma, gallbladder adenocarcinoma, ovarian carcinoma, and prostate cancer [6–12].

Further studies proved its role in many solid tumors including breast cancer [13], lung cancer [14], colorectal cancer [15], and hepatocellular carcinoma [16].

In a recent meta-analysis [17], high CD146 expression in solid tumors was associated with poor survival and might be considered as a useful prognostic biomarker and promising therapeutic target for different solid tumors.

Paucity is known about the role of CD146 in hematopoietic cells, although CD146 expression could identify a unique subset of CD3⁵CD4⁺ T-lymphocytes that may play an important role in the pathogenesis of various musculoskeletal diseases; however, its expression on activated T-cell populations as well as on a subset of murine NK cells was also reported [18, 19].
Though the biologic role of CD146 in hematologic malignancies remains to be defined, one study showed a very low number of CD146-positive AML blasts (3.3% of AML) when compared to CD146-positive B-ALL. Interestingly, all CD146-positive AML cases were classified as secondary AML not otherwise specified. Conversely, 66% of T-ALL and 36.8% of the total B-ALL cases, comprising cases bearing the t(9;22)(q34;q11)/BCR/ABL translocation, expressed CD146 on their blasts [20].

The expression of CD146 has been shown to be higher among adult B-cell ALL compared with pediatric B-cell ALL correlating with CD117, and CD64-positive cells in the former, while correlating with CD71- and CD56-positive cells in the latter [21].

Hence, the improvement of immunotyping of these tumors is important for accurate diagnostic workup of ALL; so we study through flow cytometry the expression of CD146 on CD19^+CD34^+ lymphoblasts.

![Figure 2: Flow cytometric detection of the CD146 expression on lymphoblasts.](image)

Data were expressed as number, percentage, and mean ± SD.
CD146 on different T cells, and B-cell ALL blasts trying to correlate its expression with different prognostic factors of B-cell ALL and treatment outcomes.

2. Patients and Methods

This study was a prospective case-controlled study that included 31 patients with de novo ALL presented to the South Egypt Cancer Institute (SECI), Assiut University. Twenty-eight age- and sex-matched healthy controls were also included in the study. The study was approved by the Institutional Review Board of the SECI, Assiut University. An informed written consent was taken from of all cases and controls.

All patients and controls were subjected to as follows:

(i) Thorough history taking and clinical examination, with careful assessment of clinical signs relevant to leukemia as fever, bone pain, hepatomegaly, splenomegaly, and lymphadenopathy

(ii) Complete blood pictures by Ruby Cell Dyn (American, serial number: 36026BG) and Cell Dyn 1700 (American, serial number: 513554)

(iii) Flow cytometric detection of the CD146 expression on peripheral blood T cells

Only patients were subjected to as follows:

(i) Bone marrow examination and cytochemistry study

(ii) Flow cytometric immunophenotyping using monoclonal antibodies that were used for diagnosis of ALL including CD34, CD19, CD10, CD22, and intracellular IgM. All monoclonal antibodies were purchased from Becton Dickinson (BD) Biosciences, CA, USA. The diagnosis was based on standard morphologic, cytochemical, and immunophenotypic data of the patients

(iii) Flow cytometric detection of CD146 expression on blast cells

### Table 2: Immune features of B-ALL patients and their controls with significance.

| Group          | N  | Mean   | SD    | SE    | P value |
|----------------|----|--------|-------|-------|---------|
| cd146.cd4      |    |        |       |       |         |
| Patients       | 31 | 7.5853 | 3.517 | .632  | 0.001   |
| Controls       | 27 | 2.0168 | .376  | .072  |         |
| cd146.cd8      |    |        |       |       |         |
| Patients       | 31 | 8.392  | 3.798 | .682  | 0.005   |
| Controls       | 27 | 2.1782 | .406  | .0782 |         |
| WBC            |    |        |       |       |         |
| Patients       | 31 | 32.43  | 23.618| 4.242 | NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| HG             |    |        |       |       |         |
| Patients       | 31 | 7.7677 | 1.749 | .31430| NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| PLT            |    |        |       |       |         |
| Patients       | 31 | 100.94 | 103.66| 18.617| NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| BM blast%      |    |        |       |       |         |
| Patients       | 31 | 59.0323| 21.97 | 3.94655| NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| PB blast%      |    |        |       |       |         |
| Patients       | 31 | 20.0839| 9.84  | 1.76618| NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| CD34           |    |        |       |       |         |
| Patients       | 31 | 52.3613| 21.523| 3.865 | NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| CD146.blast    |    |        |       |       |         |
| Patients       | 31 | 51.3472| 24.133| 4.334 | NA      |
| Controls       | NA | NA     | NA    | NA    |         |
| CD8            |    |        |       |       |         |
| Patients       | 31 | 10.3497| 5.409 | .9715 | NA      |
| Controls       | 28 | 19.7607| 10.509| 1.986 |         |
| Lymphocytes    |    |        |       |       |         |
| Patients       | 31 | 34.9600| 8.88  | 1.594 | 0.005   |
| Controls       | 28 | 61.3578| 12.21 | 2.306 |         |
| CD4            |    |        |       |       |         |
| Patients       | 31 | 23.1857| 4.856 | .872  | 0.003   |
| Controls       | 28 | 39.8459| 9.564 | 1.807 |         |

NA: not applicable; BM: bone marrow; PB: peripheral blast. Data were expressed as number, mean, SD, SE, and independent sample t-test used for significance.
Table 3: Relations between CD146 and different flow cytometric immune cells and blasts of ALL.

|               | CD146/CD4 | CD146/CD8 | BM blast% | PB blast% | CD34 | CD146.blast | CD8 | CD4 |
|---------------|-----------|-----------|-----------|-----------|------|-------------|-----|-----|
| **r**         | -0.001    | 0.005     | 0.926     | 0.17      | 0.422| 0.17        | 0.001| 0.517|
| **Sig.**      | 0.001     | 0.005     | 0.926     | 0.17      | 0.422| 0.17        | 0.001| 0.517|

Table 4: Impact of the mean percentages of CD146+ cells in response to induction therapy.

| CD146+ cell type | Response to induction therapy | CR Mean ± SD | <CR Mean ± SD | P value < 0.05 |
|------------------|-------------------------------|--------------|---------------|----------------|
| CD4+ cells       |                               | 6.198 ± 1.96 | 12.929 ± 2.695 | 0.001          |
| CD8+ cells       |                               | 6.640 ± 2.12 | 13.684 ± 2.94  | 0.0004         |
| Blasts           |                               | 41.560 ± 18.06 | 82.626 ± 16.82 | 0.001          |

Data were expressed as mean ± SD and independent sample t-test for significance.

2.1. Flow Cytometric Detection of the CD146 Expression on Peripheral Blood T Cells. Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood by Ficoll density gradient centrifugation (Biochrom GmbH, Germany). The cells were washed, and 2 × 10^6 cells were stained with fluorescein isothiocyanate- (FITC-) conjugated-CD146, phycoerythrin- (PE-) conjugated-CD8, and peridinin-chlorophyll-protein- (Per-CP-) conjugated-CD4 (all from BD Biosciences, CA, USA) for 20 min at 4°C in the dark. Following incubation, red blood cell lysis and washing with PBS were done. After washing, the cells were resuspended in PBS and analyzed by FACSCalibur flow cytometry with CellQuest software (BD Biosciences, USA). An isotype-matched negative control was used for each sample. Forward and side scatter histogram was used to define the blast cell population. The blast cells were gated for further analysis of the expression of CD34 and CD19. Then, the expression of CD146 was detected in CD34+CD19+ lymphoblasts. CD146 expression was defined by the percentage of lymphoblasts (Figure 2).

2.2. Flow Cytometric Detection of the CD146 Expression on Blast Cells. Fifty μl of bone marrow sample were incubated with 5 μl of FITC-anti-CD34, PE-anti-CD19, and Per-CP-anti-CD146 (all from BD Biosciences, CA, USA) for 20 min at 4°C in the dark. Following incubation, red blood cell lysis and washing with PBS were done. After washing, the cells were resuspended in PBS and analyzed by FACSCalibur flow cytometry with CellQuest software (BD Biosciences, USA). An isotype-matched negative control was used for each sample. Forward and side scatter histogram was used to define the blast cell population. The blast cells were gated for further analysis of the expression of CD34 and CD19. Then, the expression of CD146 was detected in CD34+CD19+ lymphoblasts. CD146 expression was defined by the percentage of lymphoblasts as shown in Figure 1.

2.3. Statistics. Statistical package for social sciences (SPSS) version 20 was used for data analysis. All quantitative data were expressed as mean ± standard deviation (SD). Differences in a mean between the different groups of subjects were calculated using the independent sample t-test. Pearson correlation was used to detect the relation between different quantitative variables, the Kaplan-Meier test was used to graph the survival curves of different response groups, and the log-rank test was used to find a difference; Cox regression for survival analysis was used to investigate the effect of different variables on the survival. P value < 0.05 was considered significant. Overall survival (OS) was defined as the time interval between diagnosis and death of any cause, while were expressed as percentage of CD4+ and CD8+ cells as shown in Figure 1.
disease-free survival (DFS) was set as time elapsed between diagnosis and relapse.

3. Results

This study involved pediatric patients with B-cell ALL having a median age of 6.5 years; as known for pediatric tumors, male children are exceedingly affected than female ones, so we had a male to female ratio of 1.4:1. Most patients were presented with constitutional symptoms including fever in (16/31) patients, whereby their caregivers pursued medical care, hepatomegaly, LN enlargement, and splenomegaly which were presented in 32.3%, 25.8%, and 22.6% of study patients (Table 1).

28 control children of comparable age and sex were taken for comparison of their immune cells with peers of B-cell

---

**Figure 3:** Scatter plot of the relation between CD146⁺CD4⁺ cells and OS of 31 children with B-cell ALL.

**Figure 4:** Scatter plot of the relation between CD146⁺CD8⁺ cells and OS of 31 children with B-cell ALL.
ALL where significant accumulations of CD146⁺CD4⁺ cells, CD146⁺CD8⁺ cells, CD4⁺, CD8⁺, and lymphocytes were evidenced as illustrated in Table 2.

Upon correlating different immune cells carrying CD146 antigen with each other and with other prognostic factors, we detected positive significant correlations between CD146⁺ cells with CD146⁺CD8⁺ cells ($r = +0.999$, $P < 0.001$), BM blasts ($r = +0.490$, $P = 0.005$), CD146⁺ blasts ($r = +0.910$, $P < 0.001$), and CD34⁺ cells ($r = +0.422$, $P = 0.017$). Similarly, CD146⁺CD8⁺ cells correlated significantly with BM blasts ($r = +0.494$, $P = 0.001$), CD34⁺ cells ($r = +0.420$, $P = 0.018$), and CD146⁺ blasts ($r = +0.932$, $P < 0.001$).

**Figure 5:** Scatter plot of the relation between CD146⁺ blasts and OS with 31 children with B-cell ALL.

**Figure 6:** Scatter plot of the relation between CD146⁺CD4⁺ cells and DFS.
In addition, CD146 blasts exhibited significantly positive correlations with BM blasts ($r = +0.528$, $P = 0.002$), and CD34$^+$ cells ($r = +0.405$, $P = 0.024$) (Table 3).

3.1. Relation of CD146$^+$ Cells to the Response of Treatment. Significant differences in the mean percentages of CD146$^+$CD4$^+$ cells, CD146$^+$CD8$^+$ cells, and CD146$^+$ blasts between those attained complete response to induction chemotherapy and those with less than complete response implicating that CD146 is considered a poor prognostic factor for primary response to induction therapy in B-cell ALL (Table 4).
Correlations between CD146 +CD4+ Cells, CD146 +CD8+ Cells, CD146 + Blasts, and Overall Survival and Disease-Free Survival. In our results, we found negative correlations between CD4, CD8, and blasts expressing CD146 and overall survival, where moderate negative correlation between CD146 +CD4+ cells and OS with $r = -0.506$ and $P = 0.004$ is shown Figure 3, moderate negative correlation between CD146 +CD8+ cells and OS with $r = -0.484$ and $P = 0.006$ is shown in Figure 4, and in addition, moderate negative correlation between CD146 + blasts and OS with $r = -0.466$ and $P = 0.008$ is shown in Figure 5.

With respect to disease-free survival (DFS), a significant negative impact of CD146 + cells on DFS with mild negative correlation between CD146 +CD4+ cells and DFS with $r = -0.382$ and $P = 0.034$ is shown in Figure 6, also, negative mild correlation between CD146 +CD8+ cells with
the latter with \( r = -0.390 \) and \( P = 0.03 \) is shown in Figure 7, and lastly, moderate negative correlation between CD146\(^+\) blasts and DFS with \( r = -0.438 \) and \( P = 0.014 \) is shown Figure 8.

Intuitively, negative correlations between BM blasts and OS and DFS that lived up to significance (\( P < 0.012 \) for both) were evident; in addition, significantly negative correlations between CD34\(^+\) cells with OS and DFS (\( P < 0.001 \) and \( P < 0.033 \), respectively) are all demonstrated in Table 5.

Upon doing Cox regression analysis, we found that only CD34\(^+\) cells were the most independent factor of OS (HR = 1.039, \( P = 0.014 \)), while the HR of CD146\(^+\)CD4\(^+\) cells was 2.326 (95% CI = 0.904-5.982) and was considered the highest one among different immune cells followed by HR of CD146 blasts (HR = 1.023, 95% CI = 0.955-1.096) (Table 6, Figure 9), as hazard ratio increased the risk of death from induction therapy increased.

### 3.3. DFS and OS according to Response to Induction Therapy.

Aside from the impact of immune cells expressing CD146 antigen, the median DFS for children responding completely to induction therapy was 15 ± 0.678 months (95% CI = 13.672-16.328), while for those with less than complete response, the median DFS was 8 ± 1.309 (95% CI = 5.434-10.566) with log-rank = 4.513 and \( P = 0.034 \) (Figure 10). The median OS for the former group was 22 ± 1.633 (95% CI = 18.799-25.201), while the median OS for the latter group was 13 ± 3.928 (95% CI = 5.301-25.699), with log-rank = 5.71, \( P = 0.017 \) (Figure 11).

### 4. Discussion

Advances in chemotherapy regimens, supportive care, and lastly immunotherapy of ALL resulted in a meaningful improvement of a 5-yr survival from 60% to approximately 90% for children more youthful than 15 years and from
28% to greater than 75% for adolescents elderly 15 to 19 years [22]. ALL is a disease of different prognostic factors including clinical, laboratory, genomic, cytogenetic, and immunophenotyping ones, and for efficient outcomes, adherence to risk-adapted therapy may be the way to reach the berth.

The notion to find more prognostic factors might decrease our losses of cases especially those expected to achieve better outcome; one of these factors is CD146 antigen that is expressed in various cell types to bind with unidentified ligand [5] exerting multifunctional activities as previously mentioned.

The results provided here were interesting and novel trying to uncover the role of CD146+ cells in this limited number of pediatric B-cell ALL, passing by significant accumulations of these cells in patients compared to controls to significant correlations between CD146+CD4+ cells, CD146+CD8+ cells, and CD146+ blasts with other poor prognostic features including CD34+, and BM blasts, to significant accumulations of these cells in children that did not gain CR, to finally unexpectedly worse impact of these cells on OS and DFS.

Contrary to Cavazzini et al. [20] who found that the expression of CD146+ cells was detected in 38.8% of B-cell ALL (14/38) of his retrospective series of 162 leukemic patients (ALL+AML), Xie et al. [21] tried to compare the expression rates of CD146 in adult and children’s B-ALL patients which were 29.17% and 9.09%, respectively, showing that this difference was significant ($P < 0.05$). However, all our patients expressed CD146 with variable percentages, and the mean for CD146+CD4+ cells was $7.58 \pm 3.517$, the mean expression for CD146+CD8+ cells was $8.392 \pm 3.798$, and the mean expression for CD146+ blasts was $51.347 \pm 24.133$.

CD146 was one of the most significantly expressed genes having CD equivalent in B-cell ALL switched from B-lineage to monocytoid lineage (which represented 4-6% of B-cell ALL) [23].

In a previous study, CD146 expression strongly associated with Ph+ positivity in B-ALL with the highest percentage of CD146-positive blasts in all Ph-positive B-ALL cases [20]; in our study, we did not relate the percentage of CD146 expression with that of Ph chromosome possibly because of shortage of data collection and limited awareness of this relation.

Plenty studies in solid tumors showed that increased CD146 expression was associated with short survival outcomes in patients with various cancer types. Nevertheless, these studies were small numbered and less powered, so a meta-analysis of its role in different solid tumors was introduced that scientifically estimated survival data of 2,694 solid tumor adult patients included in 12 different studies. Overall, these results clearly indicated that high CD146 expression was a poor prognostic factor in solid tumors, including poor OS (pooled HR = 2.496, 95%CI = 2.115 - 2.946, $P = 0.001$).
and poor TTP (pooled HR = 2.445, 95%CI = 1.975 – 3.027, \( P = 0.001 \)) [17]. Upon stratifying the results by cancer type, the prognostic value of CD146 overexpression was significant in gastrointestinal and lung cancers.

Conversely, no study up-to-date evaluates adequately its role in hematologic malignancies; Xie et al. [21] explored the expression of CD146 in pediatric B-cell ALL compared to its counterpart in adults and found it to be related positively to CD64 and CD117 in adults, while in children’s B-ALL, CD146 was positively related to CD71 and CD58 (\( P < 0.05 \)). In addition, CD146 was significantly associated with lower response to induction therapy in both adult and pediatric B-ALL; we partially agreed with the previous study where CD146 expression was significantly associated with higher non-CR rate, but we did not correlate its expression with CD34, BM blasts, CD8\(^+\), CD4\(^+\), and lymphocytes.

In pediatrics, CD146 is widely expressed in embryonic tissues, including neural crest and its derivatives [24], but in hematopoietic tissue, it is expressed in a subpopulation of activated T cells corresponding to <1% of all cells in PB and BM. During development, CD146 is involved in various physiological functions, including cell migration, different cellular interactions, signaling, and morphogenesis.

In addition, Pujades et al. [24] demonstrated that CD146 expression is strongly associated with adverse clinical outcomes in malignancies derived from the neural crest lineage including melanoma. More importantly, CD146\(^+\) cells were present in primary malignant rhabdoid tumors and exhibited exclusive in vivo tumorigenic potential sufficiently to suggest its utility as a potent biomarker for risk stratification and possibly treatment of malignant rhabdoid tumors.

Yet, the role of CD146 expression in pediatric B-ALL remains to be defined; we propose that CD146 will be considered for subsequent studies in pediatric ALL to better define leukemic subtypes and whether to be a potential target for subsequent therapy like melanoma.

Our study suffered from several limitations; small number of patients included in our study could be attributed to financial issues, the relation of CD146 expression to Philadelphia chromosome was missing, the difference of expression of CD146 among different risk groups of B-ALL was not touched, and by the same token, the study was not bolstered by CD146 relations to adverse genetic features including TCF3-PBX1 fusion, MLL gene rearrangement, t(17;19), hypodiploidy, and intrachromosomal amplification of chromosome 21.

**5. Conclusion**

CD146 was expressed significantly in children’s B-ALL and associated with poor prognostic features including poor response and treatment outcomes and could be a possible poor prognostic factor in pediatric B-cell ALL.
Data Availability
All data of the study are available whenever requested.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
We acknowledged all patients and controls for participating in this research; also, we acknowledged the friendly support of our colleagues and laboratory technicians.

References
[1] J. M. Ribera and A. Oriol, “Acute lymphoblastic leukemia in adolescents and young adults,” Hematology/Oncology Clinics of North America, vol. 23, no. 5, pp. 1033–1042, 2009.
[2] S. P. Hunger, X. Lu, M. Devidas et al., “Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group,” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1663–1669, 2012.
[3] J. M. Lehmann, G. Riethmuller, and J. P. Johnson, “MUC18 a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily,” Proceedings of the National Academy of Sciences, vol. 86, no. 24, pp. 9891–9895, 1989.
[4] D. Bruno, R. Jochen, G. Nathalie et al., “Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells,” Blood, vol. 111, no. 5, pp. 2631–2635, 2008.
[5] A. Ouhitit, L. G. Rajiv, and Y. A. Zakaria et al., “Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1795, no. 2, pp. 130–136, 2009.
[6] S. Loges, H. Clausen, U. Reichelt et al., “Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis,” Clinical cancer research, vol. 13, no. 1, pp. 76–80, 2007.
[7] X. Lei, C. W. Guan, Y. Song, and H. Wang, “The multifaceted role of CD146/MCAM in the promotion of melanoma progression,” Cancer cell international, vol. 15, no. 1, p. 3, 2015.
[8] G. J. Wu and E. B. Dickerson, “Frequent and increased expression of human METCAM/MUC18 in cancer tissues and metastatic lesions is associated with the clinical progression of human ovarian carcinoma,” Taiwanese Journal of Obstetrics & Gynecology, vol. 53, no. 4, pp. 509–517, 2014.
[9] W. Wang, Z. L. Yang, J. Q. Liu, S. Jiang, and X. Y. Miao, “Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma,” Tumour biology, vol. 33, no. 1, pp. 173–182, 2012.
[10] G. J. Wu, M. W. Wu, S. W. Wang et al., “Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression,” Gene, vol. 279, no. 1, pp. 17–31, 2001.
[11] K. Watson-Hurst and D. Becker, “The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion,” Cancer biology & therapy, vol. 5, no. 10, pp. 1375–1382, 2006.
[12] G. Stéphane, D. Jean-Philippe, C. J. Emmanuelle et al., “Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype,” Human pathology, vol. 38, no. 6, pp. 830–841, 2007.
[13] G. Zabouo, A. M. Imbert, J. Jacquesmier et al., “CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines,” Breast Cancer Research, vol. 11, no. 1, p. R1, 2009.
[14] G. Kristiansen, Y. Yu, K. Schlüns, C. Sers, M. Dietel, and I. Petersen, “Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer,” Analytical Cellular Pathology, vol. 25, no. 2, p. 81, 2003.
[15] B. Tian, Y. Zhang, and N. Li, “CD146 protein as a marker to predict postoperative liver metastasis in colorectal cancer,” Cancer biotherapy & radiopharmaceuticals, vol. 28, no. 6, pp. 466–470, 2013.
[16] G. Jiang, L. Zhang, Q. Zhu, D. Bai, C. Zhang, and X. Wang, “CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma,” Journal of experimental & clinical cancer research, vol. 35, no. 1, pp. 1–12, 2016.
[17] Z. Ping, L. Hai, L. Pei-Hua et al., “Prognostic value of CD146 in solid tumor: A Systematic Review and Meta- analysis,” Scientific Reports, vol. 7, no. 1, p. 4223, 2017.
[18] M. F. Elshal, S. S. Khan, N. Raghavachari et al., “A unique population of effector memory lymphocytes identified by CD146 having a distinct immunophenotypic and genomic profile,” BMC Immunology, vol. 8, p. 29, 2007.
[19] N. Despoix, T. Walzer, N. Jouve et al., “Mouse CD146/MCAM a marker of natural killer cell maturation,” European Journal of Immunology, vol. 38, pp. 2855–2864, 2008.
[20] C. Francesco, C. Diana, F. Luisa et al., “Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia,” Cytometry Part B: Clinical Cytometry, vol. 90, no. 3, pp. 247–256, 2016.
[21] X. Xiao-Qing, W. Wei-Min, G. Si-Lin et al., “Expression of CD146 in adult and children’s acute B cell lymphoblastic leukemia and its significance,” Journal of experimental hematology/Chinese Association of Pathophysiology, vol. 25, no. 1, pp. 30–34, 2017.
[22] W. L. Jae and C. Bin, “Prognostic factors and treatment of pediatric acute lymphoblastic leukemia,” Korean Journal of Pediatrics, vol. 60, no. 5, pp. 129–137, 2017.
[23] J. Sonal, M. Anurag, K. Gauri et al., “Evaluating new markers for minimal residual disease analysis by flow cytometry in precursor B lymphoblastic leukemia,” Indian Journal of Hematology and Blood Transfusion, vol. 34, no. 1, pp. 48–53, 2018.
[24] C. Pujades, B. Guez-Guez, and D. Dunon, “Melanoma cell adhesion molecule (MCAM) expression in the myogenic lineage during early chick embryonic development,” The International Journal of Developmental Biology, vol. 46, no. 2, pp. 263–266, 2002.